WHO ICTRP trial
Acipimox to improve muscle function
ISRCTN87404878 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN87404878 |
|---|---|
| Public title | Acipimox to improve muscle function |
| Scientific title | Acipimox to improve muscle function and sarcopenia – a feasibility study |
| Primary sponsor | Newcastle upon Tyne Hospitals NHS Foundation Trust |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Not Applicable |
| Countries | England;United Kingdom |
| Conditions | Sarcopenia, muscle weakness Musculoskeletal Diseases Other specified disorders of muscle |
| Interventions | Current interventions as of 08/12/2023: The trial is a before and after-comparison trial. All participants will receive the study medication (acipimox) and aspirin (some participants may be taking aspirin already, in which case they will… |
| Registration date | Jun 29, 2021 |
| Target size | 11 |
| Secondary IDs | 2021-000993-28;Nil known;CPMS 49429, Grant Codes: MC_PC_19047, IRAS 293565 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: